These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. The impact of cyclosporine on the development of immunosuppressive therapy: perspective from a transplant nephrologist involved with the development of C2. Cole E; Deshpande R Transplant Proc; 2004 Mar; 36(2 Suppl):408S-413S. PubMed ID: 15041376 [TBL] [Abstract][Full Text] [Related]
8. Optimization of cyclosporine therapy with abbreviated area under the curve method in renal transplant. Yang WC; Chen YF; King KL; Wu TH; Chen Hsu RY ; Tang JJ; Loong CC; Chou MH; Lin MF; Lui WY Transplant Proc; 2000 Nov; 32(7):1685-7. PubMed ID: 11119892 [No Abstract] [Full Text] [Related]
9. High performance liquid chromatography cyclosporine monitoring: a predictor of renal graft outcome. Cicciarelli J; Avila D; Iwaki Y; Sather H; Mendez R Transplant Proc; 1998 Aug; 30(5):1683-4. PubMed ID: 9723243 [No Abstract] [Full Text] [Related]
10. Neoral (cyclosporine) C2 monitoring in renal transplant recipients: a single-center experience in Asia. Wong HS; Morad Z Transplant Proc; 2003 Feb; 35(1):230-1. PubMed ID: 12591376 [No Abstract] [Full Text] [Related]
11. Cyclosporine level: which single-point estimation of drug level is the best? Sharma R; Kumar J; Ahmed M; Gupta A; Gulati S; Sharma AP; Bhandari M Transplant Proc; 2001; 33(7-8):3124-5. PubMed ID: 11750343 [No Abstract] [Full Text] [Related]
13. Neoral C2 monitoring in solid organ transplantation. Levy GA Transplant Proc; 2004 Mar; 36(2 Suppl):392S-395S. PubMed ID: 15041373 [No Abstract] [Full Text] [Related]
14. Abbreviated cyclosporine pharmacokinetic profiling in clinical renal transplantation: from principles to practice. Vathsala A; Lu YM Transplant Proc; 2001; 33(7-8):3137-9. PubMed ID: 11750348 [No Abstract] [Full Text] [Related]
15. Experience with conversion from Sandimmun to Neoral cyclosporine and the correlation of C2 levels with renal function. Konstadinidou I; Boletis JN Transplant Proc; 2004 Mar; 36(2 Suppl):163S-166S. PubMed ID: 15041329 [TBL] [Abstract][Full Text] [Related]
16. Cyclosporine peak concentration in relation to the four-hour absorption phase in pediatric renal graft recipients. Wigger M; Drückler E; Muscheites J; Stolpe HJ; Kundt G; Wacke R Transplant Proc; 2001; 33(7-8):3126-7. PubMed ID: 11750344 [No Abstract] [Full Text] [Related]
17. New concepts in cyclosporine monitoring. Keown PA Curr Opin Nephrol Hypertens; 2002 Nov; 11(6):619-26. PubMed ID: 12394607 [TBL] [Abstract][Full Text] [Related]
18. Low exposure to cyclosporine is a risk factor for the occurrence of chronic rejection after kidney transplantation. Citterio F; Torricelli P; Serino F; Foco M; Pozzetto U; Fioravanti P; Castagneto M Transplant Proc; 1998 Aug; 30(5):1688-90. PubMed ID: 9723245 [No Abstract] [Full Text] [Related]
19. Two-hour postdose concentration: a reliable marker for cyclosporine exposure in adolescents with stable renal transplants. John U; Ullrich S; Roskos M; Misselwitz J Transplant Proc; 2005 Apr; 37(3):1608-11. PubMed ID: 15866686 [TBL] [Abstract][Full Text] [Related]
20. Comparison of trough level and C(2) cyclosporine blood concentration monitoring in outpatient kidney transplant recipients. Braun F; Armstrong VW; Lorf T; Canelo R; Arndt C; Oellerich M; Ringe B Transplant Proc; 2001; 33(7-8):3108-9. PubMed ID: 11750336 [No Abstract] [Full Text] [Related] [Next] [New Search]